Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation.
Why Immune Cells Keep Damaging Your Eyes
This observational study analyzed vitreous proteomic profiles in eight patients with neovascular AMD receiving anti-VEGF therapy compared to…
Standard eye drops for AMD stop one problem, but a second, hidden immune attack is still hurting your vision.
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
FDA approves a new, higher-dose version of the eye medicine Eylea.
The FDA has approved Eylea HD, a VEGF inhibitor, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, …
FDA approves higher-dose Eylea to treat four eye conditions that damage the retina and threaten vision, potentially reducing how often patie…
Subretinal fibrosis develops in 40-50% of nAMD eyes after 5 years of anti-VEGF therapy, associated with worse vision
How often does scarring develop in treated macular degeneration eyes?
A systematic review and meta-analysis of 58 studies in anti-VEGF-treated nAMD eyes found subretinal fibrosis developed in approximately 10-1…
Scarring in treated macular degeneration eyes affects 10% to 15% within two years and up to half by five years, causing vision loss averagin…
FDA Approves Byooviz (ranibizumab) for Neovascular AMD, Macular Edema Following RVO, and Myopic CNV
FDA approves a new eye medicine called Byooviz for three conditions that can cause vision loss.
The FDA has approved Byooviz, a VEGF inhibitor, for intravitreal injection to treat neovascular age-related macular degeneration, macular ed…
FDA approves Byooviz to treat three eye conditions causing vision loss from leaky blood vessels in the retina.
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults.
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.